Inactive Instrument

News Bio-Path Holdings Inc Nasdaq

Equities

US09057N1028

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Bio-Path Closes $1.2 Million Share Offering	Apr. 19	MT
Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-theMarket Under Nasdaq Rules	Apr. 19	AQ
Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	Apr. 18	AQ
Bio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients	Apr. 18	AQ
Bio-Path Holdings, Inc. Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1B Clinical Trial of Bp1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients	Apr. 18	CI
Bio-Path Holdings Expands Global Patent Portfolio	Apr. 15	AQ
Bio-Path Holdings, Inc. Expands Global Patent Portfolio	Apr. 15	CI
North American Morning Briefing : Investors on Edge as High-Stakes Jobs Report Awaited	Apr. 05	DJ
Bio-Path Holdings Provides 2024 Clinical and Operational Update	Apr. 02	AQ
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q4 23	Mar. 27	NE
Bio Path : Failure to Satisfy Listing Rule - Form 8-K	Mar. 13	PU
Transcript : Bio-Path Holdings, Inc., Q4 2023 Earnings Call, Mar 08, 2024	Mar. 08
Bio-Path Holdings Reports Full Year 2023 Financial Results	Mar. 08	AQ
North American Morning Briefing : Stock Futures -2-	Mar. 08	DJ
Bio-Path Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07	CI
Bio-Path Holdings to Announce Fourth Quarter and Full Year 2023 Financial Results on March 8, 2024	Mar. 04	AQ
Bio-Path Holdings to Announce Fourth Quarter and Full Year 2023 Financial Results on March 8, 2024	Mar. 01	AQ
Reverse Split: 1 of 20	Feb. 22	FA
Bio-Path Holdings Announces 1-for-20 Reverse Stock Split	Feb. 21	AQ
Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory Relapsed Lymphoma and Refractory Relapsed Chronic Lymphocytic Leukemia Patients	Jan. 11	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Bio-Path Holdings Inc Nasdaq

Equities

US09057N1028

Summary

Filters